Viracta Therapeutics to Host Key Opinion Leader Webinar
Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial
Event to take place on Thursday, May 20th at 2:00 PM ET
News provided by
Share this article
Share this article
SAN DIEGO, May 18, 2021 /PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma on Thursday, May 20, 2021 at 2:00 PM ET.
The call will feature a presentation by KOLs
Viracta Therapeutics to Host Key Opinion Leader Webinar
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The challenge of finding a match
flcourier.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from flcourier.com Daily Mail and Mail on Sunday newspapers.
Operator
Thank you for standing by. Welcome to Schrodinger s conference call to review the company s first quarter financial results. My name is Kevin, and I ll be your operator for today s call.
[Operator Instructions]
Now, I would like to introduce your host for today s conference call, Jaren Madden, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.
Jaren Madden
Senior Vice President, Investor Relations and Corporate Communications
Thank you, and hello, everyone. Welcome to today s call during which we will provide an update on the company and review our financial results for the first quarter of 2021. Earlier this morning, we issued a press release summarizing our financial results and progress across the company, which is available on our website at www.schrodinger.com. Here with me on our call today are Ramy Farid, President and Chief Executive Officer; Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist and Hea
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
Updated Phase 2 analysis to be presented by Dr. Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai
News provided by
Share this article
Share this article
NEWARK, Calif., May 12, 2021 /PRNewswire/ Protagonist Therapeutics ( Protagonist or the Company ) (Nasdaq: PTGX), today announced that an abstract highlighting updated data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera ( PV ) has been selected for an oral presentation at the upcoming European Hematology Association ( EHA ) 2021 Annual Congress. The EHA Congress will take place virtually June 9-17, 2021. Rusfertide, a synthetic, injectable hepcidin mimetic, regulates iron homeostasis and controls the absorption, storage, and distribution of iron in the body. Rusfertide was discovered through the Company s peptide te